
GRAIL nears FDA approval for Galleri cancer test, boosting market potential and scaling costs.
GRAIL reported strong growth in its Galleri multi-cancer early detection test, completing over 174,000 tests in nine months of 2026 and seeing a 24% volume increase in Q3. A positive FDA advisory vote positions Galleri to become the first FDA-approve...





